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ABSTRACT
Molecular testing is becoming an important part of the
diagnosis of any patient with cancer. The challenge to
laboratories is to meet this need, using reliable methods
and processes to ensure that patients receive a timely
and accurate report on which their treatment will be
based. The aim of this paper is to provide minimum
requirements for the management of molecular
pathology laboratories. This general guidance should be
augmented by the speciﬁc guidance available for
different tumour types and tests. Preanalytical
considerations are important, and careful consideration
of the way in which specimens are obtained and reach
the laboratory is necessary. Sample receipt and handling
follow standard operating procedures, but some
alterations may be necessary if molecular testing is to be
performed, for instance to control tissue ﬁxation. DNA
and RNA extraction can be standardised and should be
checked for quality and quantity of output on a regular
basis. The choice of analytical method(s) depends on
clinical requirements, desired turnaround time, and
expertise available. Internal quality control, regular
internal audit of the whole testing process, laboratory
accreditation, and continual participation in external
quality assessment schemes are prerequisites for delivery
of a reliable service. A molecular pathology report
should accurately convey the information the clinician
needs to treat the patient with sufﬁcient information to
allow for correct interpretation of the result. Molecular
pathology is developing rapidly, and further detailed
evidence-based recommendations are required for many
of the topics covered here.
INTRODUCTION
The management of individual cancer patients is
increasingly inﬂuenced by speciﬁc features of the
tumour, often due to speciﬁc genetic alterations.1
The concept of personalised medicine for cancer is
not new, being variously known as individualised,
stratiﬁed, or precision medicine. Examples are now
commonplace, from oestrogen receptor and ERBB2
(HER2) ampliﬁcation in breast cancer to EGFR
mutations or ALK rearrangements in lung cancer,
BRAF mutations in malignant melanoma, RAS
mutations in colorectal cancer, and BCR/ABL1 in
Philadelphia positive chronic myeloid leukaemia.
Methods to individualise the status of a tumour
include immunohistochemistry, and molecular
pathology, which is generally taken to mean the
analysis of nucleic acids from tissue, cells or ﬂuids.2
Molecular testing is therefore becoming an essen-
tial part of the work-up for many if not most
patients with solid and haematological tumours.
As a consequence, most hospitals with an active
oncology practice require access to laboratories that
provide the necessary information on the genetic
make-up of a tumour from biopsy material. This
trend is likely to strengthen as new drugs become
available and those on the market start to be used
in combination or sequentially to overcome resist-
ance mechanisms.
The challenge to the pathologist is to go beyond
diagnosis and classiﬁcation to produce the informa-
tion required to guide treatment accurately and to do
so in as short a time as possible. The simplest way to
think about the requirements for laboratories offer-
ing these services is to consider the pathway from
patient to result, and the requirements at each stage
(ﬁgure 1). Inevitably, there will be differences
between healthcare systems and laboratories in how
they organise their work. The purpose of this frame-
work is to assist molecular pathological laboratories
in providing the best service to patients. Clear
responsibilities for requesting molecular analysis, pre-
analytical sample handling, nucleic acid extraction
and analysis, and reporting of results are prerequisites
for the operation of a safe and efﬁcient service.
One frequently asked question revolves around
the number of samples any laboratory should be
handling to be considered reliable. There are, at
present, no data to answer this question, but we
know from other settings (eg, ERBB2 (HER2)
testing3 4) that it is not wise to consider setting up
services for small numbers of patients, and indeed
it is difﬁcult to achieve a cost-effective solution for
small numbers of samples. Equally, some genes are
rarely mutated, and as laboratories adopt panel
testing as the norm, even the largest laboratories
are likely to ﬁnd that they are reporting some muta-
tions very rarely. Our belief is that the key to this
question lies in the number of samples submitted
for testing, and the clinical and logistic require-
ments of the service. The practicalities of testing
and clinical needs may, therefore, make the decision
straightforward for most tests.
Given that the number of patients requiring
testing is likely to increase, most accredited
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laboratories are likely to offer a reliable service if they adhere to
the recommendations covered in the subsequent sections,
though monitoring of this by national bodies is recommended.
It should be noted that there is separate guidance available for
the various steps in this pathway, and for individual testing
needs. An excellent example, based on a systematic review, is
the guidance recently issued by the College of American
Pathologists (CAP), the International Association for the Study
of Lung Cancer, and the Association for Molecular Pathology
(AMP), for ALK and EGFR testing in lung cancer.5 This paper is
intended to provide an overview to guide laboratories in operat-
ing a reliable service: we have incorporated many of their
recommendations and those from other relevant publica-
tions2 6–10 and the ISO15189 guidance.
REQUESTING MOLECULAR ANALYSIS
Multiple medical disciplines (eg, surgery, oncology or path-
ology) may request molecular analysis to deﬁne a treatment
strategy for individual patients, though in practice this will
usually be the oncologist. In many cases, a multidisciplinary
team (tumour board) will make the decision to request a test.
The requesting process should ensure that the request is made
appropriately, and that every patient who needs a test is offered
one in a timely manner. This is one of the most difﬁcult aspects
of operating a molecular pathology laboratory: it is important
to ensure that tests are requested on all patients who need one,
but equally that unnecessary tests are not performed. Molecular
testing is expensive, although costs are currently decreasing, and
oncologists or multidisciplinary teams may feel that they need
to manage demand, particularly if they manage the budget.
However, automatic (reﬂex) testing by pathologists based on
diagnosis and tissue availability within the pathology depart-
ment can be more efﬁcient, particularly if >10% of patients
with a particular diagnosis require testing (Cree, unpublished).
The decision to implement reﬂex testing should be based on a
business plan, taking into account the costs in time and money
of specimen retrieval from pathology archives when the result
becomes clinically necessary.6 Additionally, the amount of tissue
that can be obtained versus that required for molecular path-
ology should be included in considerations of the sampling strat-
egy: this is a particular problem in lung cancer patients. There is
also a need for ﬂexibility: technology and requirements are
changing rapidly and frequent reassessment of clinical need is
essential. Good communication is required between the labora-
tory, the oncologists, and surgeons to ensure that necessary tests
are requested timely.
Previous treatment (eg, chemotherapy) can change gene
expression11 and mutation status,12–14 and should be documen-
ted on the request form. It is important to discuss any changes
to current protocols with surgeons and pathologists, who
require clear identiﬁcation of resection margins, but also need
to accept the requirement for molecular analysis. Equally, inter-
pretation of molecular analysis requires knowledge of the diag-
nosis and available treatment strategies.
Preanalytical standards
The pathology laboratory has to be able to handle multiple
sample types. This raises a number of challenges when the
needs of molecular analysis are included within a diagnostic
pathway, though many of the issues are common to any diagnos-
tic test. At every stage, there is potential for samples to be mis-
identiﬁed, and careful attention should be given to this danger.
It is the responsibility of the person taking the specimen to
identify the patient, the sample required, ensure that the sample
is correctly labelled, ﬁxed in formalin (where necessary), and/or
dispatched to the laboratory. However, when samples are being
acquired in particular situations, such as within an operating
theatre, the primary responsibility of the operating theatre staff
is to the patient, not the sample, and thought should be given to
the need to implement and operate fail-safe procedures to
Figure 1 Workﬂow for laboratories
undertaking molecular pathology for
cancer patients from formalin-ﬁxed
parafﬁn-embedded (FFPE) tissue
samples.
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ensure that samples are treated correctly in order to ensure that
reliable and accurate diagnosis and test results can be obtained.
The preanalytical process has recently been examined in some
detail by the SPIDIA project (http://www.spidia.eu), the results
of which we understand are due to be incorporated into ISO
guidance (ISO 15189).
Tissue: The majority of diagnostic biopsies are small and are
ﬁxed rapidly when placed in neutral buffered formalin (4% for-
maldehyde), but larger surgical specimens require controlled ﬁx-
ation.15 16 It is probably optimal for the ﬁxation process to be
controlled by the pathology laboratory. This may involve trans-
port of fresh specimens to the pathology laboratory, preferably
under vacuum if this takes more than an hour (see below). Fresh
tumour samples may be taken for molecular analysis (or tissue
banking) in the operating theatre, but preferably or after receipt
in the pathology laboratory according to deﬁned protocols. It is
best to open bowel specimens and (where possible) to incise
larger masses to allow the penetration of ﬁxative. Formalin only
penetrates tissue at around 1 mm/h, and ﬁxation will only start
when penetration occurs. Formalin should only be used 24 h
after dilution to 4% w/v, in order to reduce the effect of poly-
merisation, and ensure a stable 4% concentration. Cold ischae-
mia occurs between removal of tissue and its ﬁxation, and is a
particular problem for large surgical specimens. It alters levels
of gene expression (at the RNA and protein level), and is a
major consideration for molecular pathology.17 Control of ﬁx-
ation time and temperature is recommended for molecular ana-
lysis of proteins such as ERBB2 (HER2) or for the analysis of
gene expression. Vacuum packing of tissue and transfer to the
laboratory at 4°C (Tissue Safe) is one option attracting attention,
and can be very useful for sites distant to the hospital labora-
tory.18 Cooling should be as rapid as possible and cold ﬁxation
preserves RNA well, though cold shock-induced changes can be
a consideration for some biomarkers.19
Standard operating procedures (SOP) should be designed for
tissue handling which incorporate aspects listed in the box 1.
Cytology samples should also be handled according to
deﬁned SOPs. In some centres, pathologists are involved in per-
forming ﬁne needle aspirations, which aids handling of the
sample. Fixation is usually in an alcoholic ﬁxative, which pre-
serves nucleic acids relatively intact. This renders such samples
suitable for most molecular analysis, though some problems
have been noted in human papillomavirus (HPV) and non-small
cell lung cancer (NSCLC) testing.20 21 22 23
Liquid biopsy: EDTA blood samples can be used to extract
nucleic acids from cells (buffy coat) and plasma. The leukocyte
fraction provides a ready source of germline DNA and has long
been used to generate molecular data for haematologic neopla-
sia. Viruses and bacteria can be isolated and identiﬁed by
molecular methods from buffy coat preparations. Cell-free DNA
can be used for mutation analysis and, although such methods
have yet to enter routine practice, they show considerable
promise.13 24 25 The preference is for plasma from EDTA
blood, sent directly to the molecular pathology laboratory or to
the blood sciences laboratory. Serum contains DNA from leuko-
cytes and is less suitable. It is feasible to use samples taken for
routine haematology measurements, but lithium heparin tubes
should be avoided, as lithium is a PCR inhibitor.
Caution should be exercised with RNA as measurement of
levels can be affected by continuing production in cells after the
specimen has been taken, and ongoing degradation by RNAse
activity. Preventative measures should be taken to minimise such
degradation of RNA, but rapid transport of samples on ice to
laboratories is not a standard procedure in most hospitals, and
establishing a cold chain or adding inhibitors to the samples as
they are taken may be difﬁcult. Specialised blood collection
tubes are available to preserve RNA (eg, PAXgene, PreAnalytix/
Qiagen; Valencia, California, USA), but their clinical use
requires validation with the tests concerned.
In clinical laboratories, all processes must have SOPs. It is
important that these are used and adhered to using work
instructions and checklists where necessary.
Sample receipt and handling
There should be a dedicated process for the receipt of samples,
which should be suitably staffed and allow accession numbers to
be allocated to samples as they enter the laboratory (as per ISO
15189, and ISO 9001). Most Laboratory Management
Information Systems (LIMS) allow this, but few have as yet
acknowledged the need for integration of molecular pathology
needs. Barcoding of samples is good practice and is encouraged.
All samples should be tracked from patient to report.
Tissue, blood and ﬂuid processing within the laboratory
should be performed to deﬁned SOPs (see ISO 15189). While
most tissue biopsy samples are received ﬁxed, fresh tissue can
also be sent to the laboratory for intraoperative frozen section-
ing or molecular analysis. This requires separate SOPs and dedi-
cated portering, nursing and laboratory staff.
Tissue samples go through a macroscopic examination and
cut-up stage, when blocks are taken and placed in bar-coded
and/or numbered plastic cassettes for processing. Spare tissue in
formalin can be retained at this stage. Vacuum or microwave-
based processors are temperature controlled devices which
ensure excellent penetration of graded alcohols and xylene sub-
stitutes, allowing parafﬁn embedding. The temperature for dif-
ferent machines and protocols can vary substantially, and this
can affect nucleic acid recovery (Cree, unpublished). The use of
ﬁxed tissue that has been previously frozen is not advised, and
decalciﬁcation reduces DNA and particularly RNA recovery.
Both have been found to produce no or suboptimal
results.26 27 28 Close collaboration between clinical teams
and histopathology laboratories is advised, and it is critical that
changes in processing are communicated to the molecular
pathology laboratory and adapted where necessary.
Histopathological diagnosis is made from stained sections cut
from parafﬁn blocks at 4–6 μm according to minimum dataset
requirements (see http://www.rcpath.org/publications-media/
publications/datasets/datasets-TP.htm). For molecular testing, it
is essential to take strict precautions to prevent cross-
contamination between samples. It is best practice to replace the
Box 1 SOPs required for tissue handling, including staff
responsibilities for each stage
▸ Patient and sample identiﬁcation using four identiﬁers
(eg, given name, surname, date of birth, hospital
identiﬁcation code).
▸ Specimen type and origin.
▸ Container type—diagrams and checklists in theatres can
help ensure correct use.
▸ Transport requirements—time and temperature.
▸ Fixation requirements, including opening bowel specimens
and incising large masses, while respecting resection
margins.
Cree IA, et al. J Clin Pathol 2014;67:923–931. doi:10.1136/jclinpath-2014-202404 925
Best practice
group.bmj.com on February 9, 2016 - Published by http://jcp.bmj.com/Downloaded from 
knife (blades) regularly (ideally before each new formalin-ﬁxed
parafﬁn-embedded (FFPE) tissue block is cut). Additionally, dis-
posable plasticware should be used to transfer sections to glass
slides (if sections are used). The use of waterbaths to stretch sec-
tions can be avoided by using a droplet of PCR quality water on
glass slides. Care should be taken that decontamination proce-
dures do not reduce DNA or RNA levels required for assay
when sections are cut. For example, the use of DNAzap wipes
on microtome blades immediately before cutting sections can
reduce DNA levels substantially, and should be avoided. The use
of substances likely to inhibit PCR should be avoided.29
It is recommended that the pathologist marks the area of the
section containing neoplasia on the H&E slide at the time of
diagnosis for macrodissection or microdissection, if used. It may
be necessary to mark multiple areas of the neoplasia for manual
microdissection to account for heterogeneity of neoplastic cell
content within large tumours. As an alternative to microdissec-
tion, 1 mm punches of marked areas may be used.30 Laser
capture microdissection is largely a research tool and not neces-
sary for routine molecular pathology.
The histopathologist should estimate the percentage of neo-
plastic cells present in the sample (or part of the sample)
selected for DNA/RNA extraction. This estimation can be
important in determining success or failure of subsequent
testing, as it may deﬁne the lower limit of detection and a
minimum percentage of neoplastic cells present can be applied
to many tests.31 If necrosis is present, this should be noted, but
is best avoided in samples for molecular analysis. Widely dis-
persed tumour cells within a sample, or lymphangitis carcino-
matosa, are both notorious examples in which a low percentage
of neoplastic cells can produce false negative results. Where the
pathologist is directly responsible for requesting the molecular
analysis, such ‘reﬂex’ testing permits rapid turnaround times
and prevents the need for retrieval of blocks at a later date,
reducing test turnaround time, reducing staff time and therefore
cost. This needs to be balanced against unnecessary testing in
patients who do not need further treatment, or who need treat-
ment at a later date when testing for mutations in alternative
genes might be needed. Clear responsibilities for the assessment
of neoplastic cell content and macrodissection or microdissec-
tion are required: this is an essential role of the histopathologist.
The estimated percentage of neoplastic cells present in the tissue
used for DNA/RNA extraction should be mentioned in the
pathology report.
Blood samples (EDTA) are usually spun down at low speed to
pellet red cells and retrieve the buffy coat, and plasma fractions.
Processing should begin as soon as possible (ideally within
30 min) after sampling. Collection time should be indicated on
the tube, and the elapsed period between sampling and process-
ing should be recorded. Cells are usually removed from plasma
by centrifugation at 1000–2000 g for 10 min using a refriger-
ated centrifuge. Centrifugation at 2000 g for 15 min also
depletes platelets in the plasma sample. Again, a protocol
should be strictly observed. It is feasible to use density centrifu-
gation to obtain white cells, exosomes, and plasma from the
same sample.32 Specimens can be ﬂagged on many LIMS for
molecular analysis and reﬂex testing may be feasible. Aliquoted
plasma samples can be stored at −80°C.
SOPs should be established for secure and, where possible,
controlled collection, handling, and storage of tissue and blood
samples, and their fractions (including extracted nucleic acids)
(see ISO 15189 and any national guidelines). Few laboratories
maintain their stores of tissue blocks and slides in temperature
controlled environments. Equally, blood samples are usually
discarded within days of receipt. Blood and blood-derived pro-
ducts are considered biohazards and should be handled accord-
ingly. Fresh tissue poses similar risk, but FFPE tissue is regarded
as safe for handling, though chemicals involved in tissue pro-
cessing need careful storage and handling.
DNA and RNA extraction
The extraction of nucleic acids for clinical use requires quality
controlled reagents, ideally IVD CE-marked. A large number of
companies produce kits, though few are sold for clinical use,
and it is the responsibility of the laboratory to validate and
verify any methods performed against existing standards. Some
multicentre validation data have been published,33 but such
direct comparisons are rare. Consideration of which method to
use should consider throughput, required quality and quantity
of DNA or RNA and intended methods of analysis.
Manual methods are commonly used. The majority of the
manual methods use precipitation-wash steps with centrifuga-
tion of spin columns or ﬁlters. Even kits require training and
considerable skill, but can provide excellent results. Special care
should be taken to avoid sample misidentiﬁcation and contamin-
ation. Careful adherence to SOPs is important—the use of
checklists and careful staff training can help.
Automated methods are useful as they can economise on staff
time and can help to prevent sample misidentiﬁcation. They
tend to use magnetic bead extraction methods, which are suited
to robotic systems. It is important to trial such systems before
implementation, as not all are adept at blood and FFPE block
extraction: several machines may be required to handle all
sample types and varying throughput.
Quantiﬁcation of DNA and RNA can be performed by spec-
trophotometry, ﬂuorometry or PCR. Different methods advo-
cate different machines: the Nanodrop spectrophotometer,
Qubit ﬂuorometer, or Agilent Bioanalyser are all widely used.
The DNA degradation in FFPE samples reduce the precision of
spectrophotometer measurement. However, quantitative real-
time PCR can be used to establish amounts, sizes and ampliﬁc-
ability of DNA and RNAwith considerable accuracy and limited
sample consumption. SOPs should indicate which validated
methods are preferred for each test performed in the laboratory,
and staff should be trained appropriately. Continuous audit of
preanalytical performance with internal quality control is
important, so that changes in specimen handling and nucleic
acid extraction can be implemented safely.
Storage of DNA and RNA should be controlled carefully.
Accession logs or barcoded vials can be used to prevent sample
misidentiﬁcation. Temperature logs should be maintained. In
general, it is good practice to
▸ store extracted DNA and RNA samples, clearly labelled, at
−20°C or −80°C, respectively
▸ store PCR products in a separate freezer at −20°C or −80°C
▸ store sequencing libraries in a separate freezer at −20°C or
−80°C.
There are insufﬁcient data on the effects of length of storage
on tissue and extracted DNA or RNA for different analytical
methods: this is a consideration likely to be of increasing
importance as patients may need tests done many years after
samples have been taken. DNA, or cDNA, is more stable than
RNA and is likely to survive many years under the conditions
given.
Choice of analytical method
Testing requirements are deﬁned by clinical need, and this, in
turn, is deﬁned by the availability of drugs for which actionable
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mutations have been identiﬁed (table 1). This list is expanding
rapidly, and individual laboratories need to coordinate their
testing with the needs of oncologists on a regular basis.34 In
some cancers, mutations are mainly located in a few exons (‘hot-
spots’) and rarely found elsewhere within the gene. As the goal
is to identify actionable mutations, laboratories should screen
for all mutations with clinical evidence of efﬁcacy. For instance,
in the EGFR gene, mutations in exon 18 should be systematic-
ally screened even if they represent less than 5% of the identi-
ﬁed alterations. National guidelines may also indicate minimum
requirements (eg, Germany requires testing on biomarkers of
1% or more incidence).
In many laboratories, there is a move away from single-gene
assays towards panel testing, and to reﬂect this change in prac-
tice. External quality assessment (EQA) schemes are, or have
moved to, tumour-speciﬁc schemes, distributing tumour
samples for testing of multiple genes depending on individual
laboratory practice (http://www.ukneqas-molgen.org.uk/; http://
www.esp-pathology.org). Such schemes expect the currently
relevant actionable mutations to be tested, but will also assess
the genotyping accuracy for other gene tests where this is
appropriate.
Other considerations in making the choice of analytical
method are the number of samples that require testing, the
number of genes being tested, and the percentage of mutations
tested for in each gene. Most pathology laboratories now have
real-time PCR machines that are perfectly capable of running
well-established kits that cover 95% of the actionable mutations
in a particular gene. Sanger and pyrosequencing methods are
also widely available. In high throughput units, it may be eco-
nomical to use next-generation sequencing (NGS) platforms,
which have the advantage of a more extensive coverage of an
increasing number of genes of interest. The amount of tissue
available is often the limiting factor as to the extent of the
testing performed (eg, ﬁne needle aspirate, endoscopic or
needle biopsy) and may inﬂuence which technology is chosen.
The degree of staff expertise, equipment and infrastructure
required should also be considered. Many workﬂows in molecu-
lar pathology require separation of stages in different compart-
ments (ideally rooms) to prevent DNA and RNA contamination.
Separation of pre-PCR and post-PCR steps is particularly
important.
ISO15189 requires thorough validation of in-house tests com-
pared to CE-marked in vitro diagnostic (CE-IVD) tests.
However, because most tests are only part of the whole process,
the complete procedure including preanalytic, analytic and post-
analytic phases should be validated in-depth.
These considerations typically determine the choice of tech-
nology. In practice, the options are based on real-time PCR or
sequencing solutions. Companies providing such options have
been assessed independently for EGFR (http://www.nice.org.uk/
dg9) and KRAS mutation testing (http://guidance.nice.org.uk/
DT/14), but limited data is available on many methodologies.
The pace of change in technology is considerable and no recom-
mendations are made here, other than to state that instruments
and kits should usually be IVD CE-marked, and assays validated
against existing performance speciﬁcations. Validation and veriﬁ-
cation of tests is important, both within consortia of companies,
academic and hospital laboratories, and by individual laborator-
ies offering tests for clinical use. Batch-to-batch variation is a
particular problem for complex reagents, and several mutation
detection kits have shown problematic ﬂuctuations in perform-
ance in recent years. ISO15189 requires checks on new batches
of reagents on the premise that nothing should be assumed to
work without rigorous checking.
It is likely that panel testing will become widespread within a
few years.35 Indeed, some labs are already moving to array or
NGS methods that have the advantage of providing information
on mutations in multiple genes without requiring unattainable
amounts of DNA or RNA. The NCCD (http://www.nccn.org)
have recently recommended panel testing for NSCLC, indicating
its general acceptance. It should be noted that NGS is sensitive
to low-level genetic alteration during PCR steps in the process,
and the incorporation of bioinformatics rules in data analysis
are necessary to allow correct and appropriate interpretation.
For instance, formalin induces C>T artefacts in DNA which
may mimic mutations needed to be recognised by the bioinfor-
matics approach
Performance of molecular tests
It is essential to monitor the performance of all tests within
pathology laboratories to ensure that all measurable parameters
remain within acceptable limits, as deﬁned in the validation
report for the test. In most cases, these are deﬁned statistically
based on known variation. Using simple statistics it is possible to
establish CIs within which the assay is behaving correctly (eg,
Shewart rules36 37). For example, manufacturers of kits often
(though not always) provide internal controls or reference
genes, the levels of which should not vary for the same DNA
input. While variation between samples is common, this should
not exceed certain parameters, deﬁnable from the standard
operating procedure. In-house tests should use externally
sourced controls wherever possible.
Table 1 Examples of actionable genes for solid tumours
Tumour type Genes Abnormality Drugs/indication
Non-small cell lung cancer EGFR Activating mutation Response to EGFR TKI* treatment
ALK Translocations Response to crizotinib treatment
Melanoma BRAF Activating mutation Response to vemurafenib treatment
KIT Activating mutation Response to imatinib treatment
GIST KIT Activating mutation Response to imatinib treatment
Colorectal cancer KRAS Activating mutation Resistance to anti-EGFR treatment
NRAS Activating mutation Resistance to anti-EGFR treatment
BRAF Activating mutation Poor prognosis and possible resistance to anti-EGFR treatment
Breast cancer ERBB2 (HER2) Amplification Response to trastuzumab or lapatinib treatment
BRCA1/2 Mutation Response to PARP inhibitors
Ovarian cancer BRCA1/2 Mutation Response to PARP inhibitors
*EGFR TKI—tyrosine kinase inhibitors active against EGFR, such as gefitinib and erlotinib.
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The percentage of mutations detected for individual tumour
types can vary depending on the population tested, but results
outside national conﬁdence limits should always be questioned.
Again, experience from HER2 testing is apposite and it should
be noted that knowledge of this came from a long-term database
project to collect data from many laboratories taking part in
EQA schemes.3 The percentage of patients with a particular
mutation may reﬂect ethnic mix, environmental factors, and age
distribution. These may be very different to the demographics
within clinical trials of particular drugs and result in consider-
able differences in treatment within populations.
Turnaround time is often used by healthcare managers to
judge services, and can be a blunt tool. The timeliness of reports
is critical to patient care and depends on patient pathways in
practice in individual centres. For example, the requirement for
EGFR testing in lung cancer is usually <5 working days, with a
maximum of 10 working days,5 but for reﬂex testing of high-
risk melanoma or colorectal cancer, when the results go into the
patient’s notes for later use if they require treatment, then
obtaining the results within a month may be sufﬁcient.
Acceptability of longer turnaround time may permit greater
control of testing (demand management) or batching of samples
to improve the cost effectiveness of testing. For all laboratories,
regular participation in external quality assessment is needed to
verify and improve the quality of testing, as described below.
Continuity planning is a further issue: the solution to pro-
blems with equipment due to breakdowns or limited staff avail-
ability should not be allowed to interrupt a service. Sending
samples away to another laboratory may be necessary, but ensur-
ing that alternative equipment or staff is available can prevent
cessation of service and avoid patients having to wait for treat-
ment decisions. The referring laboratory should check the
service standards of laboratories used for referral.
REPORTING MOLECULAR PATHOLOGY TESTS
FOR CANCER PATIENTS
A pathology report should accurately convey the information
the clinician needs to treat the patient on whom the test was
performed, with sufﬁcient information to allow correct inter-
pretation of the result. The key is therefore accurate communi-
cation. This is often a challenge, given the different groups of
clinicians involved and the variable capabilities of laboratory
information management systems. There is an urgent need for
greater communication between scientists, pathologists, oncolo-
gists and surgeons, so that all groups are educated to use and
interpret tests, their results and associated treatments
appropriately.38 39
Various bodies have deﬁned what should appear in a molecu-
lar pathology report.40 The American College of Surgeons
Commission on Cancer (ACS-CoC) in concert with the CAP
developed checklists that contain all the scientiﬁcally validated
data elements that are to be reported for cancer specimens.41–44
Molecular pathology external quality assessment schemes
across Europe score the report as well as the test result, and
help to guide and educate laboratories as to what should be
included in a report.2 39 The European Society of Pathology has
produced guidance for these schemes that has deﬁned how
reports will be marked, and this will drive the response of
laboratories.2 Equally, laboratories across Europe are usually
required to have accreditation. For instance, in the UK, this is by
the UK Accreditation Service (UKAS), ISO 15189 or equivalent,
and the inspectors look closely at reports and reporting stan-
dards. In Germany, the labs that pass the nationwide round
robin tests performed by QuiP (Quality in Pathology, a joint
quality assurance programme of the German Society of
Pathology and the German Association of Pathologists) are pub-
lished, which gives clinicians and patients the possibility to
check their reliability. Italy has a similar policy operated by the
Italian Association of Medical Oncology (AIOM) and the Italian
Society of Pathology (SIAPEC) that organise their external
quality assessment schemes.45 46 Finally, there are internal con-
siderations in many hospitals and laboratories, often due to clin-
ician or pathologist preferences. A suggested format is shown at
(http://kras.eqascheme.org/info/public/education/example_
reports.xhtml).
The folowing are the three key areas that should be present
within reports.
1. Patient identiﬁcation
The patient must be identiﬁed correctly – laboratories require
a minimum of two unique patient identiﬁers plus a unique
sample identiﬁer to be present on the request form and report.
These include the patient name (family name), date of birth,
hospital and national identiﬁcation number. The ward or
service, date of biopsy, and referring clinician name should also
be stated.
2. Reporting style and content
▸ Long reports are rarely read in full, and length matters; one
page, or better still, single-screen reports are preferred pro-
vided that they are legible. If reports are more than one page
in length then each page should have appropriate patient
identiﬁers in order to be linked to the correct patient, and
the pages should be numbered, that is, page 1 of 3, so the
reader of the report is aware if any pages are missing (see
also ISO 15189 for guidance).
▸ Clear presentation of the results, the test(s) performed, and
any limitations of the tests (eg, were all possible mutations
tested, or just a selection of the common ones?). For some
tests, the percentage of the sample occupied by the target of
the test (eg, neoplastic cells) is important. Ideally, the report
should contain basic information about ﬁxation (ﬁxative,
time of ﬁxation, etc.) for quality control, though this may be
held within the departmental records rather than reported.
▸ The name of the individual taking responsibility for the test
and contact details are important, and some form of author-
isation with date.
▸ Due to legal regulations in some European countries, the
pathologist who is ﬁnally responsible for the combined
‘morphological-molecular report’ must be clearly identiﬁable.
▸ Spell checkers are useful for preventing spelling and typo-
graphical errors.
3. Interpretation
The result of the test must be correctly reported and inter-
pretation provided, particularly where this involves a treatment
decision. Genotyping results should be given according to
HGVS nomenclature (http://www.hgvs.org/mutnomen/) at the
DNA level and the protein level, with appropriate reference
sequences provided. External quality assurance schemes require
laboratories to provide accurate interpretation of the result(s)
obtained and include any relevant advice. Care should be taken
to ensure this advice is as up to date as possible, and if conﬂict-
ing data is published then this should be included in the report.
In view of the growth of companion diagnostic tests in molecu-
lar pathology, pathologists may increasingly be required to
include the clinical interpretation with advice on treatment
options. The type and extent of molecular analysis used should
be clearly described to allow oncologists to request further
testing if the clinical situation warrants this.
4. Integrated reporting
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There is a widely acknowledged need for integrated reporting
of results, and as the introduction of gene panel testing becomes
more widespread then the results of the different gene tests
should be reported on one report. Also, results from several
pathology specialties on individual patients need to be inte-
grated into the same report. For instance, a patient with an
enlarged lymph node may have a biopsy and blood sample pro-
viding reports from histopathology, microbiology, immunology,
molecular pathology, haematology and biochemistry. The clin-
ician treating the patient has to integrate these with radiological
and clinical investigations to make optimal decisions. While it is
helpful to have all the pathology results within a single report,
not all countries have integrated pathology services. Different
reporting times and systems can also make this very difﬁcult to
achieve. The best solution seems to be a combined reporting
system, or electronic patient record, that permits the clinician or
multidisciplinary team to determine whether they have all the
information available to enable reasoned conclusions.
Accreditation and quality assurance—internal and external
We believe that all laboratories providing molecular pathology
services should have laboratory accreditation according to ISO
15189 or their national equivalent. Accreditation provides
patients, staff, service users and commissioners with evidence of
laboratory competence. The standards include the provision of
adequate facilities, trained staff and documentation. We recom-
mend that as part of this accreditation, laboratories should
ensure that their companion diagnostic tests cover all relevant
genes that appear in the Summary of Product Characteristics
(SmPC) published for the drug.
Laboratories that want to proceed towards accreditation
should contact their national accreditation body (NAB).47 Most
NABs have formal application documents to be ﬁlled out, and
require preliminary documentation on the laboratory itself and
the existing quality management system (QMS). The accredit-
ation body will then appoint a lead assessor and a technical asses-
sor(s) who are experts in the ﬁeld. This team of assessors will
conduct the audit (external audit) in the laboratory and they will
formally report the assessment ﬁndings to the NAB. In case of
minor non-compliances, the assessor will later check whether the
corrective actions were adequate, through submitted documenta-
tion. In case of major non-compliances, a new on-site assessment
may be required to assess the effectiveness of the corrective
actions. Accreditation may be granted for a period of up to 3 or
5 years, but the NABs will perform surveillance visits to ensure
that the laboratory continues to meet requirements, which is typ-
ically every 1–2 years. The procedure for renewal of accreditation
is usually very similar to the one for new applicants, but the
laboratory might consider at that moment to widen the scope of
the accreditation by adding new tests.
All laboratories performing molecular tests for cancer patients
should be part of an EQA scheme (eg, (http://kras.eqascheme.
org); (http://lung.eqascheme.org); (http://www.ukneqas-molgen.
org.uk); (http://www.emqn.org/emqn/schemes); (http://www.
qcmd.org)).31 48 Indeed, in most countries, continued accredit-
ation requires EQA and regular audit of test performance.49
European providers of molecular pathology EQA schemes for
solid tumours have published minimum acceptable standards of
such EQA schemes, and have signed up to meeting these stan-
dards. While there are still variations in practice between indi-
vidual schemes, the principles are now agreed.2
There has been less written about the need for internal
quality assessment. The use of control materials within each run
is recommended where the technique allows this. The results of
internal control testing should be monitored to assure
end-to-end performance of the test.50 Internal controls should
be run with all batches. Internal positive controls can be pre-
pared from samples with sufﬁcient surplus material to permit
this, or bought from commercial sources. Standardised products
should be used to assure the stability and the external validation
of the results. In some countries, national reference centres may
provide control material, and although amounts are often
limited, they can be helpful as a check on internally generated
control material.
The errors picked up by EQA fall into several categories.
Misidentiﬁcation at all stages of the testing process is an issue,
resulting in incorrect assignment of mutation or wild-type
results and, ultimately, incorrect treatment of the patient.
Genotyping errors do occur, often from human error, not fol-
lowing SOPs, and performing methods suboptimally. Careful
internal validation of tests is essential, and recording lot and
batch numbers can save weeks of investigation with manufac-
turers. Interpretative errors are less common, and likely to be
picked up by clinical teams if the data presented does not match
the conclusion. It is therefore essential that the results of the test
and the interpretation are stated in the report.
It is essential that those participating in EQA schemes read
the reports that detail errors made by all participants and act on
recommendations made, as well as ensuring that their own
errors are corrected rapidly. Poor performing laboratories
should cease their service immediately, perform a root cause
analysis and review cases that may have been affected by sys-
temic errors. They should send samples to another provider
until certain that their testing is safe. While in some countries
EQA providers can and do report poor performing laboratories
to regulators, this is not the case across Europe.49 49 In either
case, it is incumbent on the heads of laboratories to act on EQA
results and ensure patient safety.
Training and expertise
Staff availability and training should be in line with accreditation
requirements for each country. The level of training required to
operate some machines is minimal, though it can be extensive,
but the interpretation of results is often complex. Complexity of
testing procedures and interpretation are increasing with the
growing demand of testing of a panel of genes on limited mater-
ial and the accompanying introduction of NGS techniques. Staff
with appropriate competencies must be available at every stage
of the preanalytical pathway, to extract nucleic acids, to perform
the analysis, to interpret and report the results, and to take clin-
ical responsibility for their transmission to the oncologist. For
instance, in most of Europe, the ultimate responsibility for a
diagnosis on tissue and cytological material and the report to
the patient’s physician rests with the pathologist (of any discip-
line) who authorises the report. It is important that he or she
has sufﬁcient knowledge of the analytical requirements for
molecular pathology. Equally, clinical or molecular scientists per-
forming such tests need to know how their analytical require-
ments match the available samples. Both need to understand the
consequences of their work for the patient, including treatment
decisions.
It is good practice to establish molecular pathology with a
multidisciplinary team with technical, scientiﬁc and medical
staff that provides feedback and training for staff as well as
excellence for patients. The Dutch Society of Pathology has
recently started a 2-year training programme to educate molecu-
lar biologists in molecular pathology (http://www.pathology.nl),
and the Royal College of Pathologists has a fellowship
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curriculum in molecular pathology for clinical scientists under
development. In the USA, a molecular pathology curriculum for
medical laboratory scientists has recently been published by the
AMP.51 With the complexity of data obtained by next-gener-
ation-sequencing, bioinformatics experts are likely to join the
molecular pathology team in the near future.
It is essential to ensure that staff receive regular opportunities
for continuous professional development. In a fast-moving ﬁeld
such as molecular pathology, the need for staff at every level to
be up to date with new developments and trained at each stage
of the process is considerable and should be factored into the
costs of running a safe and effective service.
Research and development
Molecular pathology is developing rapidly as the technology
improves, new anticancer drugs come to the clinic, and inter-
pretation of results becomes apparent. Laboratories involved in
this work are encouraged to take part in research, and for
many it is an integral part of their practice. For these new tar-
geted therapies, laboratories should be aware that the bio-
marker which has been clinically validated in conjunction with
the therapy to deﬁne the patient population most likely to
beneﬁt will, in almost all cases, have been tested using an IVD
(CE Mark) with speciﬁc performance characteristics including a
deﬁned cut-off value. It is recommended that if an IVD is to
be substituted, then the laboratory direct comparison of the
new test with the IVD is undertaken to ensure accurate patient
selection using the alternative test. Contributing test data to
databases (ensuring it is clear as to what methodology has been
employed) is an obvious example, but evaluation of new tech-
nologies against existing tests, or exploring the health econom-
ics of test strategies are all important. Close cooperation
between molecular pathologists, clinicians designing clinical
studies involving companion diagnostics, and research-
orientated pharmaceutical industry is necessary. There is estab-
lished guidance for the reporting of diagnostic validation—
STAndards for the Reporting of Diagnostic accuracy
studies (STARD, http://www.stard-statement.org), as part of the
EQUATOR network of research report standards (http://www.
equator-network.org/toolkits).
CONCLUSION
Molecular pathology is developing rapidly and there is a danger
that guidance becomes outdated by the time it is published. As
Nils Bohr said, ‘Prediction is hard, especially about the future’.
However, given the need for guidance, the European Society of
Pathology and RCPath groups have decided to promulgate this
general guidance as best practice, and will produce more
detailed guidance on individual aspects of this paper as
necessary.
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Take home messages
▸ Molecular testing is becoming an important part of the
diagnosis of any patient with cancer.
▸ To meet this need, laboratories need to use reliable methods
and processes to ensure that patients receive a timely and
accurate report on which their treatment will be based.
▸ This paper provides guidance on the minimum requirements
for the management of molecular pathology laboratories
and should be augmented by the speciﬁc guidance available
for different tumour types and tests.
▸ Preanalytical considerations are important, and careful
consideration of the way in which specimens are obtained
and reach the laboratory, is necessary.
▸ The choice of nucleic acid extraction and analytical method
depends on clinical need, desired turnaround time,
equipment and expertise available.
▸ Laboratory accreditation, internal quality control, and
continual participation in external quality assessment
schemes are prerequisites for delivery of a reliable service.
▸ Molecular pathology reports should be integrated with the
histopathology report, and should be discussed in
multidisciplinary team meetings.
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